PL3886814T3 - Stały preparat farmaceutyczny zawierający kwas liponowy i jego zastosowanie - Google Patents

Stały preparat farmaceutyczny zawierający kwas liponowy i jego zastosowanie

Info

Publication number
PL3886814T3
PL3886814T3 PL19824070.7T PL19824070T PL3886814T3 PL 3886814 T3 PL3886814 T3 PL 3886814T3 PL 19824070 T PL19824070 T PL 19824070T PL 3886814 T3 PL3886814 T3 PL 3886814T3
Authority
PL
Poland
Prior art keywords
pharmaceutical preparation
lipoic acid
preparation containing
solid pharmaceutical
containing lipoic
Prior art date
Application number
PL19824070.7T
Other languages
English (en)
Inventor
Satishkumar Jain
Parminder Singh Sidhu
Paul Robinson
Madhura REGE
Sundareswarakumar Chellaswamy
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Publication of PL3886814T3 publication Critical patent/PL3886814T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
PL19824070.7T 2018-11-26 2019-11-26 Stały preparat farmaceutyczny zawierający kwas liponowy i jego zastosowanie PL3886814T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201831044436 2018-11-26
PCT/US2019/063135 WO2020112699A1 (en) 2018-11-26 2019-11-26 Solid pharmaceutical preparation containing lipoic acid and use thereof

Publications (1)

Publication Number Publication Date
PL3886814T3 true PL3886814T3 (pl) 2025-04-07

Family

ID=68966006

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19824070.7T PL3886814T3 (pl) 2018-11-26 2019-11-26 Stały preparat farmaceutyczny zawierający kwas liponowy i jego zastosowanie

Country Status (8)

Country Link
US (1) US11986460B2 (pl)
EP (1) EP3886814B1 (pl)
CN (1) CN113164396B (pl)
AU (1) AU2019386979B2 (pl)
BR (1) BR112021008602A2 (pl)
MX (1) MX2021005888A (pl)
PL (1) PL3886814T3 (pl)
WO (1) WO2020112699A1 (pl)

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0334340B1 (en) 1988-03-23 1994-11-09 Seiko Instruments Inc. Optically switching ferroelectric liquid crystal light valve
DE4317646A1 (de) 1993-05-27 1994-12-01 Asta Medica Ag Tabletten mit Thioctsäure und mindestens einer basischen Komponente
DE19705555A1 (de) 1997-02-13 1998-08-20 Ulrich Dr Posanski Pharmazeutische Präparate der Thioctsäure zur oralen Anwendung
US6197340B1 (en) 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US20050085498A1 (en) * 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
DE19938098A1 (de) 1999-08-12 2001-02-15 Woerwag Pharma Gmbh & Co Feste Arzneimittelformulierung mit hohem Gehalt an Thioctsäure (alpha-Liponsäure)
US6495177B1 (en) 1999-08-13 2002-12-17 Warner Chilcott Laboratories Ireland Limited Orally dissolvable nutritional supplement
US20020102301A1 (en) 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
WO2003079819A1 (en) * 2002-03-27 2003-10-02 Anglo French Drugs And Industries Ltd. Dietary supplement composition and a process of manufacturing said composition
AU2002254546A1 (en) 2002-04-03 2003-10-20 Mitchell A. Avery Lipoic acid analogs useful as provitamins and antioxidants
ATE514418T1 (de) 2002-11-12 2011-07-15 Elan Pharma Int Ltd Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
US20050147620A1 (en) 2004-01-05 2005-07-07 Karl Bozicevic Cinnamon formulation for reducing cholesterol and/or glucose levels
US8728535B2 (en) * 2005-08-04 2014-05-20 Vertical Pharmaceuticals, Llc Nutritional supplement for use under physiologically stressful conditions
AU2007276874B2 (en) 2006-07-28 2010-08-19 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
EP2572705B1 (en) 2007-10-01 2017-09-13 Laboratorios Lesvi, S.L. Orodispersible tablets
US20090270469A1 (en) 2008-04-25 2009-10-29 Auspex Pharmaceuticals, Inc. Substituted oxazolidinones
KR101209319B1 (ko) 2008-04-29 2012-12-06 한올바이오파마주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
US20100021573A1 (en) 2008-07-22 2010-01-28 Michael J Gonzalez Compositions and methods for the prevention of cardiovascular disease
US8575218B2 (en) * 2009-09-28 2013-11-05 The University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from tissues and formulations therefor
TWI400089B (zh) 2009-11-24 2013-07-01 Nippon Soda Co 羥烷基纖維素微粒子
CA2784407A1 (en) 2009-12-17 2011-07-14 Cima Labs Inc. Abuse-resistant formulations
IT1403587B1 (it) 2010-12-17 2013-10-31 Laborest Italia S P A Composizione per il trattamento di disordini metabolici
US20130084272A1 (en) 2011-09-29 2013-04-04 Philippe Perrin Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols
CA2854054C (en) 2011-12-02 2020-05-12 Pegasus Laboratories, Inc. Amphipathic lipid-based sustained release compositions
EP2809316A1 (en) 2012-01-31 2014-12-10 Mahmut Bilgic Synergisctic combination comprising a meglitinide derivative and lipoic acid
ITMI20120661A1 (it) 2012-04-20 2013-10-21 Giellepi S P A Composizione per il trattamento delle neuropatie
ITMI20130349A1 (it) 2013-03-07 2014-09-08 Laborest Italia S P A Composizione per uso nel trattamento della sindrome dell ovaio policistico
US20140271890A1 (en) 2013-03-14 2014-09-18 Thaer Ahmad Controlled-release pharmaceutical composition
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
US10588890B2 (en) 2017-05-30 2020-03-17 Biommunity, Inc. Compositions and methods to regulate hormonal cascades in stress disorders
TWI751379B (zh) 2017-09-21 2022-01-01 奧孟亞股份有限公司 用於遞送胜肽之藥物組合物
WO2019087054A1 (en) 2017-11-01 2019-05-09 Zenvision Pharma Llp Novel pharmaceutical composition comprising dpp-4 inhibitor, alpha-lipoic acid and vitamin b12

Also Published As

Publication number Publication date
MX2021005888A (es) 2021-06-23
EP3886814A1 (en) 2021-10-06
BR112021008602A2 (pt) 2021-08-03
EP3886814B1 (en) 2025-02-19
AU2019386979B2 (en) 2023-03-16
AU2019386979A1 (en) 2021-04-29
US11986460B2 (en) 2024-05-21
WO2020112699A1 (en) 2020-06-04
US20200163934A1 (en) 2020-05-28
CN113164396A (zh) 2021-07-23
CA3116354A1 (en) 2020-06-04
CN113164396B (zh) 2023-11-03

Similar Documents

Publication Publication Date Title
IL279464A (en) Pharmaceutical formulation of odevixibat
IL289925A (en) Adenosine derivative and pharmaceutical composition comprising the same
ZA202000439B (en) Liposome compositions comprising weak acid drugs and uses thereof
GB201620066D0 (en) Solid Pharmaceutical dosage formulations and processes
EP3706741A4 (en) PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL280376A (en) The history of boronic acid, its preparation and pharmaceutical preparations containing it
IL273339A (en) Griseofulbin compound and its medical use
PT3380525T (pt) Formulações farmacêuticas e métodos que as utilizam
EP3297640A4 (en) Pharmaceutical co-crystal composition and use thereof
SG11202010124SA (en) Stable pharmaceutical formulation
IL272806B1 (en) The history of boronic acid, its preparation and pharmaceutical preparations containing it
IL276311A (en) Methyllactam ring compound and its pharmaceutical use
ZA202006570B (en) Pharmaceutical formulations
SG10202008700VA (en) α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF
IL276323A (en) 4-Methyldihydropyrimidinone compounds and their pharmaceutical use
IL276430A (en) A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use
PL3326619T3 (pl) Stałe doustne kompozycje farmaceutyczne zawierające tenofowir i emtrycytabinę
ZA202001174B (en) Pharmaceutical compositions containing hyaluronic acid and carnosine and relative use
IL281217A (en) Pharmaceutical composition for controlled release of weak acid drugs and uses thereof
EP3497080A4 (en) PHARMACEUTICAL FORMULATIONS AND THEIR USE
GB2595406B (en) Pharmaceutical composition containing acetominophen and ibuprofen
ZA201804275B (en) Oral pharmaceutical composition comprising taste-masked n-acetylcysteine
GB201721604D0 (en) An oral liquid pharmaceutical composition of lamotrigine`
PT3646864T (pt) Medicamento contendo pemafibrato
ZA202006346B (en) Pharmaceutical preparation